Is long-acting repeatable octreotide an effective primary therapy for patients with acromegaly?

被引：0
|
作者：
Vivien S Bonert
机构：
[1] David Geffen School of Medicine,VS Bonert is a Professor in the Department of Medicine at Cedars Sinai Medical Center
[2] University of California,undefined
[3] Los Angeles,undefined
[4] CA,undefined
[5] USA.,undefined
来源：
Nature Clinical Practice Endocrinology & Metabolism | 2008年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：18 / 19
页数：1
相关论文
共 50 条
  • [21] BIOEQUIVALENCE OF OCTREOTIDE LONG-ACTING REPEATABLE RECONSTITUTED IN A NEW VEHICLE VERSUS OCTREOTIDE LONG-ACTING REPEATABLE IN THE CURRENT VEHICLE: OPEN-LABEL, RANDOMIZED, PHASE I STUDY.
    Shen, Guoxiang
    Roberts, John
    Roessner, Katja
    Brueck-Scheffler, Antje
    Prakash, Anadya Tripathi
    Sarp, Severine
    ONCOLOGY NURSING FORUM, 2015, 42 (02) : E206 - E206
  • [22] Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly
    Kendall-Taylor P.
    Miller M.
    Gebbie J.
    Turner S.
    Al-Maskari M.
    Pituitary, 2000, 3 (2) : 61 - 65
  • [23] Successful pregnancy in a woman with acromegaly treated with octreotide long-acting release
    Serri, O
    Lanoie, G
    ENDOCRINOLOGIST, 2003, 13 (01): : 17 - 19
  • [24] Efficacy of the Long-Acting Repeatable Formulation of the Somatostatin Analogue Octreotide in Postoperative Dumping
    Arts, Joris
    Caenepeel, Philip
    Bisschops, Raf
    Dewulf, Dominiek
    Holvoet, Lieselot
    Piessevaux, Hubert
    Bourgeois, Stefan
    Sifrim, Daniel
    Janssens, Jozef
    Tack, Jan
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2009, 7 (04) : 432 - 437
  • [25] A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly
    Trainer, Peter J.
    Ezzat, Shereen
    D'Souza, Gwyn A.
    Layton, Gary
    Strasburger, Christian J.
    CLINICAL ENDOCRINOLOGY, 2009, 71 (04) : 549 - 557
  • [26] A 12-month randomized crossover study on the effects of Lanreotide Autogel and Octreotide long-acting repeatable on GH and IGF-I in patients with acromegaly
    Andries, Magdalene
    Glintborg, Dorte
    Kvistborg, Annette
    Hagen, Claus
    Andersen, Marianne
    CLINICAL ENDOCRINOLOGY, 2008, 68 (03) : 473 - 480
  • [27] Octreotide Long-Acting Release (LAR)A Review of its Use in the Management of Acromegaly
    Lily P. H. Yang
    Gillian M. Keating
    Drugs, 2010, 70 : 1745 - 1769
  • [28] Octreotide long-acting release (LAR) - A review of its use in the management of acromegaly
    McKeage, K
    Cheer, S
    Wagstaff, AJ
    DRUGS, 2003, 63 (22) : 2473 - 2499
  • [29] Octreotide Long-Acting Release (LAR) A Review of its Use in the Management of Acromegaly
    Yang, Lily P. H.
    Keating, Gillian M.
    DRUGS, 2010, 70 (13) : 1745 - 1769
  • [30] Octreotide Long-Acting Release (LAR)A Review of its Use in the Management of Acromegaly
    Kate McKeage
    Susan Cheer
    Antona J. Wagstaff
    Drugs, 2003, 63 : 2473 - 2499
12345